NA
SURF

NewEdge Advisors’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

NewEdge Advisors’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-116
Closed -$81 – 3672
2023
Q1 		$81 Hold
116
– – ﹤0.01% 3347
2022
Q4 		$0 Buy
+116
New +$114 ﹤0.01% 4255

Other funds holding SURF

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NewEdge Advisors's SURF Position: Q2 2023 in Review

NewEdge Advisors sold out of Surface Oncology, Inc. Common Stock (SURF) in Q2 2023, closing a stake of 116 shares — an estimated $81 sold.

NewEdge Advisors first reported a position in SURF in Q4 2022 and held it in 2 quarters. The position peaked at $81 in Q1 2023. 61 funds tracked by Wall St. Rank hold SURF as of Q2 2023.

  • NewEdge Advisors reported no remaining Surface Oncology, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • NewEdge Advisors sold 116 Surface Oncology, Inc. Common Stock shares in Q2 2023, an estimated $81.
  • NewEdge Advisors first reported a position in Surface Oncology, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • NewEdge Advisors's Surface Oncology, Inc. Common Stock position peaked at $81 in Q1 2023.
  • 61 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q2 2023.

Based on NewEdge Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.